In a retrospective observational study, critically ill COVID-19 patients admitted to theICU with the CoV-2 delta-variant between august 2021 and february 2022 were evaluated(ethics application nr. 129/22 of the ethics commssion of the university Ulm.
According to the recommendations, IgG seronegative SARSCoV2-Spike antibody (< 0,80 U/ml)
COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab,
1200 mg (600 mg of each). Patients with CRP > 75 mg/l or IL-6 > 75 ng/l were treated with
one dose of intravenous tocilizumab 8 mg/kg body weight. 28-day mortality and 30-day time
course of leukocyte counts and serum concentrations of C-reactive protein (CRP),
procalcitonin (PCT), interleukin 6 (IL-6) and ferritin in 4 patient groups, i. e.,
treated without (N) or with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in
combination of both (C + T), were evaluated.
Drug: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)
IgG seronegative SARSCoV2-Spike antibody (< 0,80 U/ml) COVID-19 patients were treated
with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients
with CRP > 75 mg/l or IL-6 > 75 ng/l were treated with one dose of intravenous
tocilizumab 8 mg/kg body weight
Other Name: casirivimab / imdevimab,tocilizumab
Inclusion Criteria:
- Clinical diagnosis of COVID-19
- CoV-2 delta-variant
- critically ill patients
- ICU
Exclusion Criteria:
- tuberculosis
- active hepatitis
- HIV
Clinic of Anesthesiology
Ulm 2820256, Germany
Manfred Weiss, MD, Principal Investigator
University of Ulm